New Preclinical Data for Novel Immunotherapy Bispecific Candidate ALG.APV-527 Presented by Aptevo Therapeutics and Alligator Bioscience at Prominent Industry Conferences
Amarin’s REDUCE-IT Cardiovascular Outcomes Study Reaches 100% Mark for Estimated Onset of Target Primary Major Adverse Cardiovascular Events
pharmaceutical investing Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
pharmaceutical investing Edge Therapeutics Provides Update following Interim Analysis of Phase 3 NEWTON 2 Study of EG-1962
Organovo Division Samsara Sciences Announces Multi-Year Supply Agreement With Lonza Bioscience Solutions
